. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: Paediatr Drugs. 2015 Aug;17(4):283–301. doi: 10.1007/s40272-015-0128-2

Table 2.

Pathways Blocked in Uveitis

Recognizes	Mechanism	Name	Type of Biologic	Studies in JIA-U
Tumor Necrosis Factor-α (TNF α)	Blocks inflammation mediated by TNF α	Etanercept	Soluble receptor	Y^*
		Infliximab	Chimeric mAb^*	Y
		Adalimumab	Humanized mAb	Y
IL-17α	Interferes with TH17 function	Secukinumab	Humanized mAb	N^*
IL-6-receptor	Interferes with TH17 function and promote Treg function	tocilizumab	Humanized mAb	Y
IL-12/IL-23	Interfere with TH1 differentiation NK, CD8+ T cell function	Ustekinumab	Humanized mAb	N
IL-1 receptor	Blocks IL-1 function	Anakinra,	IL-1 R antagonist	N
IL-1beta	Blocks IL-1 function	Canakinumab	mAb	N
IL-2R-alpha (CD25)	Blocks IL-2 signaling	Daclizumab^§	Humanized mAb	C^*
B7	T cell/APC co-stimulation	Abatacept	CTLA4Ig fusion protein	C
CD20	Depletes B cells (save pro-B and plasma cells)	Rituximab	Chimeric mAb	C

mAb, monoclonal antibody; Y, yes; N, no, C, case reports.

Inline graphic Not yet on the market.

^§

Withdrawn from US market.